Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

4.61USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
505,163
52-wk High
$6.55
52-wk Low
$1.17

Select another date:

Thu, Nov 16 2017

BRIEF-‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6

* ‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​ Source text: [http://bit.ly/2A4glhH] Further company coverage:

BRIEF-Endocyte Q3 loss per share $0.55

* Q3 loss per share $0.55 Source text for Eikon: Further company coverage:

BRIEF-Endocyte Inc files for mixed shelf of upto $150 million

* Endocyte Inc says in addition, selling stockholders may offer and sell, up to 5.3 million shares of co's common stock‍​ Source text: (http://bit.ly/2i7ELz2) Further company coverage:

BRIEF-Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc

* Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing Source text : (http://bit.ly/2gyKxWH) Further company coverage:

BRIEF-Endocyte announces worldwide license of its radioligand therapy

* Endocyte announces exclusive worldwide license of phase 3 ready PSMA-targeted radioligand therapy for development in prostate cancer

BRIEF-Endocyte says ABX GmbH eligible for milestones of up to $160 mln under license agreement

* Endocyte Inc - ‍ABX is eligible for regulatory and commercial milestones of up to $160 million, and tiered royalties beginning in mid-teens​

BRIEF-Endocyte Q2 loss per share $0.28

* Endocyte reports second quarter financial results and provides clinical and pipeline update

Select another date: